Framycetin sulfate

产品说明书

Print
Chemical Structure| 4146-30-9 同义名 : 硫酸新霉素B ;Neomycin B sulfate; Fradiomycin B sulfate; Framycetin sulphate; Framycetin(sulfate)
CAS号 : 4146-30-9
货号 : A664527
分子式 : C23H52N6O25S3
纯度 : 97%
分子量 : 908.88
MDL号 : MFCD00144873
存储条件：

Pure form Keep in dark place, inert atmosphere, store in freezer, under -20°C

In solvent -20°C:3-6个月-80°C:12个月
溶解度 :

H2O: 250 mg/mL(275.06 mM)，配合低频超声助溶
动物实验配方：
生物活性
描述 Neomycin B sulfate (Framycetin sulfate), an aminoglycoside antibiotic, is a potent RNase P cleavage activity inhibitor with a Ki of 35 μM. Neomycin B sulfate competes for specific divalent metal ion binding sites in RNase P RNA. Neomycin B sulfate inhibits hammerhead ribozyme with a Ki of 13.5 μM. Neomycin B sulfate is sensitive to pH and an increase in pH suppresses the inhibition in other systems[1]. 5″-azido neomycin B and Framycetin sulfate selectively inhibit production of the mature miRNA, boosts a downstream protein, and inhibits invasion in HCC (hepatocellular carcinoma) cell line[2]. Neomycin B exhibits poor antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa, while kanamycin A shows weak activity against MRSA, methicillin-resistant Staphylococcus epidermidis (MRSE) and P. aeruginosa. Polyguanidinylation of the neomycin B-derived headgroup lowers the hydrophobic requirement of the lipid tail segment to provide broad-spectrum antibacterial activity from C16 to C12. Moreover, guanidinylation of the polycationic headgroup in neomycin B-derived cationic lipids enhances antibacterial activity against a neomycin B-, kanamycin A- and gentamicin-resistant P. aeruginosa strain, and reduces haemolytic activity[3]. Neomycin B has been found to block the binding of HIV-1 Rev protein to its viral RNA recognition site, thereby inhibiting the production of the virus[4].
实验方案
1mg 5mg 10mg

1 mM

5 mM

10 mM

1.10mL

0.22mL

0.11mL

5.50mL

1.10mL

0.55mL

11.00mL

2.20mL

1.10mL
参考文献

[1]Mikkelsen NE, Brännvall M, Virtanen A, Kirsebom LA. Inhibition of RNase P RNA cleavage by aminoglycosides. Proc Natl Acad Sci U S A. 1999 May 25;96(11):6155-60

[2]Childs-Disney JL, Disney MD. Small Molecule Targeting of a MicroRNA Associated with Hepatocellular Carcinoma. ACS Chem Biol. 2016 Feb 19;11(2):375-80

[3]Bera S, Zhanel GG, Schweizer F. Antibacterial activity of guanidinylated neomycin B- and kanamycin A-derived amphiphilic lipid conjugates. J Antimicrob Chemother. 2010 Jun;65(6):1224-7

[4]Nishizono N. [Synthesis of biomimetic analogs of neomycin B]. Yakugaku Zasshi. 2002 Jul;122(7):465-9. Japanese